FDA will ask outside experts to review Capricor’s therapy for Duchenne muscular dystrophy
And other biotech updates, brought to you by The Readout.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we explore how an ambitious nonprofit is taking control of a shelved gene therapy, as it seeks to create a new model for commercializing treatments no longer deemed lucrative by pharma. Also, we see global scientific worry over internal NIH emails that say international collaborations may be cut off.
